Fulgent Genetics (FLGT) Expected to Announce Earnings on Thursday

Fulgent Genetics (NASDAQ:FLGT) is projected to release its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of ($0.46) per share and revenue of $94.00 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Fulgent Genetics Stock Up 0.3%

Shares of NASDAQ:FLGT opened at $19.63 on Wednesday. The firm’s 50 day moving average price is $19.20 and its 200 day moving average price is $19.38. The stock has a market cap of $557.51 million, a price-to-earnings ratio of -8.21 and a beta of 0.89. Fulgent Genetics has a fifty-two week low of $13.46 and a fifty-two week high of $31.04.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on FLGT. Wall Street Zen upgraded shares of Fulgent Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Fulgent Genetics in a report on Monday, July 6th. Finally, Piper Sandler restated a “neutral” rating and issued a $15.00 price target (down from $30.00) on shares of Fulgent Genetics in a research note on Tuesday, May 5th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Fulgent Genetics has an average rating of “Hold” and a consensus price target of $27.00.

Insider Transactions at Fulgent Genetics

In related news, COO Jian Xie sold 2,146 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $38,391.94. Following the completion of the sale, the chief operating officer directly owned 367,605 shares of the company’s stock, valued at $6,576,453.45. This represents a 0.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Hanlin Gao sold 1,688 shares of Fulgent Genetics stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $30,198.32. Following the transaction, the insider directly owned 990,374 shares in the company, valued at approximately $17,717,790.86. This trade represents a 0.17% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 5,980 shares of company stock valued at $106,360. Insiders own 36.18% of the company’s stock.

Institutional Investors Weigh In On Fulgent Genetics

Several hedge funds have recently modified their holdings of the stock. RTW Investments LP purchased a new stake in shares of Fulgent Genetics in the fourth quarter valued at approximately $18,521,000. JPMorgan Chase & Co. raised its position in Fulgent Genetics by 767.0% in the third quarter. JPMorgan Chase & Co. now owns 299,014 shares of the company’s stock worth $6,758,000 after acquiring an additional 264,524 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Fulgent Genetics by 89.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 348,533 shares of the company’s stock worth $9,156,000 after acquiring an additional 164,535 shares in the last quarter. Wells Fargo & Company MN raised its position in Fulgent Genetics by 261.1% in the fourth quarter. Wells Fargo & Company MN now owns 120,781 shares of the company’s stock worth $3,173,000 after acquiring an additional 87,329 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in Fulgent Genetics in the fourth quarter valued at $2,177,000. 48.06% of the stock is owned by institutional investors and hedge funds.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.